ArticleThe Lancet. Oncology2024
Premature mortality trends in 183 countries by cancer type, sex, WHO region, and World Bank income level in 2000-19: a retrospective, cross-sectional, population-based study.
Article in The Lancet. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- The projected rise of pancreatic cancer mortality in Italy: forecasts until 2035.Updates in surgery · 2026Article
- Global, regional, and national impact of epidemic disasters on health workforce equality between 1990 and 2019: An ecological and modeling study.PLoS medicine · 2026Article
- Mucus and tumor penetrating paclitaxel micelles for potent local therapy of cervical cancer.Journal of nanobiotechnology · 2026Article
- Allostatic load associated with all-cause and cause-specific mortality: a large prospective cohort study.BMC public health · 2026Article
- Premature mortality from respiratory disease attributable to PMInternational journal of occupational medicine and environmental health · 2026Article
- Benchmarking progress in cause-specific cancers in China: a nationwide analysis of premature mortality from 1990 to 2023.The Lancet regional health. Western Pacific · 2026Article
- A pH-responsive mesoporous Zn-MOF nanocarrier for efficient cisplatin delivery and inhibition of A549 cancer cells.Journal of materials science. Materials in medicine · 2026Article
- Global trends and disease burden of elderly male breast cancer, 1990-2021: a population-based study.Frontiers in endocrinology · 2026Article
- Evaluating the role of BMI in survival and complications in older esophageal squamous cell carcinoma following esophagectomy.Oncology reviews · 2026Article
- Phytochemical basis and antitumor mechanisms ofFrontiers in immunology · 2026Review
- Development and psychometric evaluation of the cancer bio-psycho-social-spiritual comprehensive assessment scale.BMC psychology · 2025Article
- Long-term outcomes of minimally invasive esophagectomy vs. open esophagectomy in older patients with esophageal squamous cell carcinoma: a propensity score matching analysis.Langenbeck's archives of surgery · 2025Article
- Article
- Global patterns and trends in cancer-related premature death and their impact on life expectancy across 185 countries: a population-based analysis.Military Medical Research · 2025Article
- Feasibility of acquiring occupational data from cancer patients' medical records in Malaysian oncology centres.BMC public health · 2025Article
- Burden of pancreatic cancer among the Western Pacific Region and association with human resources for health from 1990 to 2021: Results from the Global Burden of Disease Study 2021.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Premature mortality projection for diabetes to 2030: a subnational evaluation towards the Healthy China 2030 Goals.Frontiers of medicine · 2025Article
- Article
- Counties with Low Employment and Education Status Are Associated with Higher Age-Adjusted Cancer Mortality.Cancers · 2025Article
- Controllable nickel ions release from deferoxamine mesylate-triggered nickel-iron layered double hydroxide for eliciting apoptotic cell death in prostate cancer.Journal of nanobiotechnology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
backgroundCancer is a leading cause of mortality worldwide. By 2040, over 30 million new cancers are predicted, with the greatest cancer burden in low-income countries. In 2015, the UN passed the Sustainable Development Goal 3.4 (SDG 3.4) to tackle the rising burden of non-communicable diseases, which calls for a reduction by a third in premature mortality from non-communicable diseases, including cancer, by 2030. However, there is a paucity of data on premature mortality rates by cancer type. In this study, we examine annual rates of change for cancer-specific premature mortality and classify whether countries are on track to reach SDG 3.4 targets.
methodsThis is a retrospective, cross-sectional, population-based study investigating premature mortality trends from 2000-19 using the WHO Global Health Estimates data. All cancers combined and thirteen individual cancers in 183 countries were examined by WHO region, World Bank income level, and sex. The risk of premature mortality was calculated for ages 30-69 years, independent of other competing causes of death, using standard life table methods. The primary objective was to compute average annual rate of change in premature mortality from 2000 to 2019. Secondary objectives assessed whether this annual rate of change would be sufficient to reach SDG 3.4. targets for premature mortality by 2030.
findingsThis study was conducted using data retrieved for the years 2000-19. Premature mortality rates decreased in 138 (75%) of 183 countries across all World Bank income levels and WHO regions, however only eight (4%) countries are likely to meet the SDG 3.4 targets for all cancers combined. Cancers where early detection strategies exist, such as breast and colorectal cancer, have higher declining premature mortality rates in high-income countries (breast cancer 48 [89%] of 54 and colorectal cancer 45 [83%]) than in low-income countries (seven [24%] of 29 and four [14%]). Cancers with primary prevention programmes, such as cervical cancer, have more countries with declining premature mortality rates (high-income countries 50 [93%] of 54 and low-income countries 26 [90%] of 29). Sex-related disparities in premature mortality rates vary across WHO regions, World Bank income groups, and by cancer type.
interpretationThere is a greater reduction in premature mortality for all cancers combined and for individual cancer types in high-income countries compared with lower-middle-income and low-income countries. However, most countries will not reach the SDG 3.4 target. Cancers with early detection strategies in place, such as breast and colorectal cancers, are performing poorly in premature mortality compared with cancers with primary prevention measures, such as cervical cancer. Investments toward prevention, early detection, and treatment can potentially accelerate declines in premature mortality.
fundingWHO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.